Intellia Therapeutics
Clinical trials sponsored by Intellia Therapeutics, explained in plain language.
A gene-editing company using CRISPR technology to develop therapies for genetic diseases.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
CRISPR therapy takes on rare swelling disorder
Disease control OngoingThis phase 3 trial tests a one-time gene editing treatment called NTLA-2002 for people with hereditary angioedema (HAE), a rare genetic condition causing sudden, painful swelling attacks. About 80 participants will receive either the treatment or a placebo. The goal is to see if …
Phase: PHASE3 • Sponsor: Intellia Therapeutics • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Gene therapy aims to stop painful swelling attacks in hereditary angioedema
Disease control OngoingThis study tests a new treatment called NTLA-2002 for adults with hereditary angioedema (HAE), a condition that causes sudden, painful swelling attacks. The therapy uses gene editing to lower a protein that triggers these attacks. The goal is to see if it is safe and can reduce h…
Phase: PHASE1, PHASE2 • Sponsor: Intellia Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Gene therapy for HAE: does it last? new study tracks Long-Term safety
Disease control ENROLLING_BY_INVITATIONThis study follows about 100 people with hereditary angioedema who previously received the gene-editing therapy NTLA-2002. Researchers will monitor side effects and how well the treatment controls swelling attacks over time. The goal is to understand if a single dose can provide …
Sponsor: Intellia Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Gene Editing's lasting impact: a Long-Term look at NTLA-2001
Knowledge-focused ENROLLING_BY_INVITATIONThis study follows people who previously received NTLA-2001, an experimental gene-editing therapy, for a type of amyloidosis that can affect nerves or the heart. The goal is to monitor long-term safety and see if the therapy's effects on disease markers persist over time. Partici…
Sponsor: Intellia Therapeutics • Aim: Knowledge-focused
Last updated Aug 05, 2026 00:00 UTC